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Abstract

Author Manuscript

The 2013–2015 outbreak of Ebola virus disease in Guinea, Liberia, and Sierra Leone was
unprecedented in the number of documented cases, but there have been few published reports on
immune responses in clinical cases and their relationships with the course of illness and severity of
Ebola virus disease. Symptoms of Ebola virus disease can include severe headache, myalgia,
asthenia, fever, fatigue, diarrhea, vomiting, abdominal pain, and hemorrhage. Although
experimental treatments are in development, there are no current U.S. Food and Drug
Administration–approved vaccines or therapies. We report a detailed study of host gene expression
as measured by microarray in daily peripheral blood samples collected from a patient with severe
Ebola virus disease. This individual was provided with supportive care without experimental
therapies at the National Institutes of Health Clinical Center from before onset of critical illness to
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recovery. Pearson analysis of daily gene expression signatures revealed marked gene expression
changes in peripheral blood leukocytes that correlated with changes in serum and peripheral blood
leukocytes, viral load, antibody responses, coagulopathy, multiple organ dysfunction, and then
recovery. This study revealed marked shifts in immune and antiviral responses that preceded
changes in medical condition, indicating that clearance of replicating Ebola virus from peripheral
blood leukocytes is likely important for systemic viral clearance.

Introduction
During the 2013–2015 Ebola virus disease (EVD) outbreak in Guinea, Liberia, and Sierra
Leone, the World Health Organization reported 28, 616 cases with 11, 310 deaths (1, 2).
This outbreak, caused by a Makona variant of Ebola virus (EBOV), had an estimated 40%
case fatality rate (3, 4).

Author Manuscript
Author Manuscript

EBOVs infect numerous cell types, including monocytes, macrophages, dendritic cells
(DCs), endothelia, epithelia, and hepatocytes (3). Infection leads to suppression of antiviral
responses, alterations in proinflammatory responses, and immune cell dysregulation (5, 6).
Severe EVD in humans occurs after EBOV exposure to non-intact skin or mucosa. Clinical
illness onset follows an average incubation of 6 days and is characterized by neuromuscular
weakness, fever, and asthenia (7–9). High-level viremia and broad tissue tropism result in
widespread infection (10). Complex pathogenesis due to direct viral-mediated cellular injury
and indirect host-mediated injury contributes to multiple organ dysfunction (MOD) (11).
Hypovolemic shock, attributable to gastrointestinal fluid losses from recurrent episodes of
emesis and large-volume watery diarrhea, contributes to tissue ischemia and mortality (8).
Although much has been learned about EVD in humans from this recent large outbreak,
detailed molecular studies of EVD in humans are critical because significant gaps remain in
our knowledge of the molecular aspects of disease and associated clinical correlates.

Author Manuscript

Here, daily global gene expression responses were measured in peripheral blood from a 34year-old male health care worker exposed to EBOV in Sierra Leone and evacuated to
National Institutes of Health (NIH) on day 7 (d7) of clinical illness through onset of critical
illness and recovery (12). This patient received supportive care without experimental
therapies and, after recovery and viral clearance from blood, was released from the hospital
on d33. Kinetics of gene expression were characterized using Pearson correlation and
principal components analyses (PCAs) to identify key transition points. Gene ontology and
pathway mapping of these major transition points, and the overall gene expression response,
were performed to characterize host responses that correlated with EVD, including
replication of virus in peripheral blood leukocytes (PBLs), serum viral load, coagulopathy,
critical illness, and recovery.
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Results
PBL global gene expression response shows distinct phases correlating with viral
replication and different stages of illness

Author Manuscript

To determine the kinetics of viral replication in PBLs and its effect on gene expression, we
performed strand-specific quantitative reverse transcription polymerase chain reaction (qRTPCR) to measure both EBOV nucleoprotein (NP) mRNA as a marker of active viral
replication and NP vRNA as a marker of presence of virions. EBOV NP mRNA was
detected from d7 to d11, peaked at d9 [cycle threshold (Ct) = 31], and then declined to
below detection by d12 (Fig. 1A). EBOV NP vRNA was detected from d7 to d14, peaked at
d8 to d9 (Ct = 29), and then decreased to below detection by d15. These data showed that
PBL EBOV replication, as indicated by the presence of NP mRNA, ceased by d12, and the
presence of EBOV genomic RNA, as measured by NP vRNA, was cleared from PBLs by
d15. The peak of PBL-associated EBOV NP mRNA and vRNA on d8 to d9 approximated
the peak of serum EBOV glycoprotein (GP) RNA on d7 to d8, reported previously (12).
EBOV RNA in PBLs peaked just before the patient was downgraded to critical condition on
d10. The level of PBL-associated NP mRNA showed a sudden rise on d7 to d9, suggesting
that during the start of infection, rapid replication in a small population of cells, likely
myeloid cells, drove serum EBOV RNA to peak on d9.

Author Manuscript

Microarrays were used to measure gene expression responses in PBLs on 21 of the 26 days
of inpatient care (d7 to d22, d24, d25, d28, d31, and d33) and 4 outpatient visits (d59, d103,
d180, and d270). Expression values from the patient's PBL at each time point were
compared to expression in a pool of PBL RNA from 29 healthy adult donors. This analysis
showed that 8660 sequences were differentially expressed with at least a twofold change in
concentration in at least 30% of time points (Fig. 1B). Pearson analysis was performed to
understand the relationship between gene expression changes and patient's course of EVD.
A two-dimensional similarity matrix (Fig. 1C), composed of pair-wise Pearson correlation
coefficients of gene expression levels, showed highest similarity between samples taken on
d7 to d13 (phase 1), d14 to d21 (phase 2), d22 to d24 (phase 3), and d25 to d28 (phase 4)
and during outpatient visits between d59 and d270 (phase 5). This analysis showed that gene
expression responses in PBLs underwent several phases from onset of critical illness through
recovery, generally preceding changes in clinical classification.
Gene expression differences correlated with changes in serum EBOV RNA levels

Author Manuscript

Correlation analysis was next performed using clinical data, including EBOV GP RNA in
serum (systemic viral load), EBOV NP mRNA in PBLs (viral replication in PBLs), D-dimer
and platelet counts (coagulopathy), and serum creatinine as a surrogate marker for critical
illness. Pearson analysis was performed to identify host transcripts whose expression
correlated with kinetics of serum EBOV GP RNA, with a Pearson correlation coefficient of
≥0.6. This value was chosen to maximize our ability to identify transcripts whose expression
levels changed in accordance with changes in serum EBOV GP RNA levels and to identify
subtle transition points in host responses during the course of inpatient illness. Similar to
PBL gene expression in Fig. 1C, the Pearson similarity matrix (Fig. 2A) revealed four
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phases with three major transition points in gene expression responses that were positively
correlated (n = 2690) and negatively correlated (n = 1071) with serum EBOV GP RNA Ct
values (Fig. 2B). These marked transitions in gene expression profiles occurred on d13 to
d14 (phase 1 to 2), d20 to d21 (phase 2 to 3), and d25 to d28 (phase 3 to 4).

Author Manuscript

Gene ontology mapping of positively correlated transcripts showed activation of antiviral,
inflammatory, oxidative stress, DNA damage, cell death, and wound healing responses (table
S1). Antiviral responses included type I interferon (IFN) signaling and pattern recognition
receptor signaling, whereas immune and inflammatory responses included innate immune
response markers, antigen processing, and presentation of peptide antigen via major
histocompatibility complex (MHC) class I, response to IFN-γ, leukocyte activation, cellular
response to cytokine stimulus, regulation of interleukin-6 production, and response to stress.
A marked increase in expression of genes involved in response to oxidative stress and DNA
damage was also observed, including signal transduction by p53, G1 DNA damage
checkpoint, response to DNA damage, and activation of cell death responses, including
apoptotic signaling, tumor necrosis factor (TNF)– mediated signaling, and regulation of
programmed cell death, along with expression of genes involved in coagulation, wounding,
and repair responses.
Gene ontology analysis of transcripts negatively correlated with serum EBOV GP RNA Ct
values was dominated by repair-related pathways, including regulation of ion transport, cellcell signaling, anatomical structure morphogenesis, anatomical structure development, cell
differentiation, system development, and multicellular organism development. Intriguingly,
49% of sequences (n = 529) negatively correlated with serum EBOV GP RNA Ct values
were unmapped using gene ontology terms (table S2).

Author Manuscript

To identify host responses underlying these transitions, we directly compared gene
expression profiles of d13 and d14, d20 and d21, and d25 and d28 (Fig. 2, C to E). Analysis
of individual transition points, phase 1 to 2 (d13 to d14), phase 2 to 3 (d20 to d21), and
phase 3 to 4 (d25 to d28), revealed that different pathways dominated different transition
points.
Gene expression correlated with host response transition on d13 to d14 of illness

Author Manuscript

To determine pathways differentiating d13 to d14, we directly compared the expression of
transcripts positively correlated with serum EBOV GP RNA Ct values on these days. This
analysis identified 1695 transcripts ≥1.5-fold more highly expressed on d13 relative to d14
and 655 transcripts ≥1.5-fold more highly expressed at d14 relative to d13 (Fig. 2C).
Ontology analysis of transcripts with higher d13 expression showed enrichment of antiviral,
innate immune, inflammatory, reactive oxygen species (ROS), and cell death responses
(table S3). These included type I IFN signaling, response to IFN-γ, regulation of cytokine
secretion, respiratory burst by NADH (reduced form of nicotinamide adenine dinucleotide)–
dependent system producing hydrogen peroxide, super-oxide anions and hydroxyl radicals,
positive regulation of nitric oxide synthase biosynthesis, regulation of TNF superfamily
production, and regulation of endopeptidase activity involved in apoptotic signaling.

Sci Transl Med. Author manuscript; available in PMC 2018 April 12.
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Gene ontology analysis of transcripts with higher d14 expression was dominated by cell
proliferation and adenosine 5′-triphosphate (ATP) biosynthesis, ubiquitin-mediated
proteolysis, and DNA damage (including mitochondrial DNA damage), and DNA damage–
associated cell cycle arrest, nuclear factor κB (NF-κB)–inducing kinase (NIK)/ NF-κB
signaling, and chromatin assembly (table S4). The d13 to d14 transition was also associated
with induction of MHC class II genes in peripheral blood (fig. S1), and serum
immunoglobulin analysis showed that Ebola- and GP-specific immunoglobulin Gs(IgGs)
were detected starting on d13 to d14 (fig. S2).
Gene expression correlated with host response transition on d20 to d21 of illness

Author Manuscript

An identical approach was used to identify transcripts with ≥1.5-fold higher expression on
d20 versus d21. This analysis identified 550 transcripts with higher expression on d20 and
431 transcripts with elevated expression on d21 (Fig. 2D). Gene ontology analysis showed
that transcripts with higher d20 expression (n = 550) were dominated by innate immune
response markers, cytokine-mediated signaling, defense response to virus, mitotic cell cycle
process, and regulation of protein metabolic process (table S5). In contrast, gene ontology
analysis of transcripts with higher d21 expression showed repair, oxidative phosphorylation,
and metabolic responses, including respiratory electron transport chain, nucleoside
triphosphate metabolism, cellular respiration, mitochondrial ATP synthesis–coupled electron
transport, oxidative phosphorylation, and glycosyl compound metabolism (table S6). The
d20 to d21 transition was also associated with appearance of neutralizing antibodies (fig.
S3), clearance of EBOV GP RNA from serum, a decrease in total PBL counts, end of renal
and respiratory failure, and upgrading from critical to serious condition.
Gene expression correlated with host response transition on d25 to d28 of illness

Author Manuscript

The d25 to d28 transition was similarly assessed and identified 132 transcripts with ≥1.5fold higher expression on d25 relative to d28 (Fig. 2E). The lack of enriched biological
processes was likely due to the small number of sequences (table S7). However, several type
I IFN-stimulated genes (ISGs), including IFITM1, IFITM2, IFITM3, IFIT1, IFI6, and
SOCS3, were identified. Several neutrophil function–related genes (MPO and CD177) and
innate inflammatory response–related genes (IL1R2, LY96, MMP9, and TNFAIP6) were
also present. Apoptosis-related genes (including DEDD2 and OLFM4) were also identified
with higher expression on d25. Several genes (SOCS3, IL1R2, TNFAIP6, and OLFM4) are
negative regulators of cytokine-related responses, suggesting a role in down-regulating
inflammatory and apoptosis-related responses.

Author Manuscript

Gene ontology of sequences with ≥1.5-fold higher d28 expression (n = 1688) showed
activation of antigen presentation–related responses and a slight reactivation of antiviral and
inflammatory responses (table S8), although with much lower expression than was observed
on d7 to d13 (fig. S4). These included response to type I IFN signaling, positive regulation
of leukocyte-mediated immunity, IFN-γ–mediated signaling, antigen processing and
presentation of exogenous peptide antigen via MHC class I, and Fc-γ receptor signaling and
phagocytosis.
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To characterize the effect of EBOV replication and clearance from PBLs on host gene
expression in PBLs, we performed correlation analysis (Pearson coefficient ≥ 0.6) using
PBL EBOV NP mRNA Ct values. This analysis identified transcripts (n = 444) with
expression levels that correlated with PBL EBOV replication (Fig. 3A). Ontology analysis
revealed significant enrichment for antiviral, inflammatory, and cell death–related responses
(table S9), including type I IFN signaling, IFN-γ–mediated signaling, cytokine-mediated
signaling, and positive regulation of programmed cell death. Cell death– and immune
response– correlated genes included CASP1, CASP4, RIPK3, CXCL1, IL1B, IL2RG, LY96,
and high levels of C2 (>20-fold increase at peak between d8 and13). This population was
dominated by expression of type I ISGs that markedly decreased between d13 and d14 (Fig.
3B). These genes included canonical ISGs, such as ADAR, IRF7, IRF9, OAS1, OAS2,
OAS3, IFIT1, IFIT3, MX1, IFI35, IFI44, ISG15, and IFI6. Multiplex qRT-PCR was also
performed on a subset of type I IFNs and ISGs and showed that three type I IFN genes
(IFNB1, IFNA6, and IFNA21), cytosolic viral RNA sensor (IFIH1), and ISGs (IFI27, IFI44,
IFI6, IFIT1, IFIT2, IFIT3, ISG15, MX1, and OAS1) were more highly expressed on d13.
(Fig. 3C; additional qRT-PCR data in fig. S5). Transcripts with higher d14 expression were
related to activation of lymphocytes, including IFNG and IRF4, and may represent a shift
from an innate immune cell–dominated response on d13 to a lymphocyte-predominant
response on d14. Direct comparison of cytokine signaling and cell death–related pathways
on d13/d14 showed that these were similarly more highly expressed at d13 than on d14 (Fig.
3, D and E, respectively). Thus, the transition between phases 1 and 2 was driven
predominantly by decreased antiviral response–related gene expression and an increase in
adaptive immune response markers.

Author Manuscript

Gene expression associated with distinct phases of innate and adaptive immune
responses
Expression profiles of inflammatory mediators (n = 3518) were examined to identify
immune response markers critical for controlling viral replication and mediating viral
clearance. Of these, 1029 transcripts showed at least a twofold difference in expression
relative to normal controls in at least four time points. A correlation matrix, composed of
pairwise Pearson correlation coefficients of transcript expression values, demonstrated high
similarity between samples taken on d7 to d13 (phase 1), d14 to d21 (phase 2), d22 to d24
(phase 3), and d25 to d270 (phase 4) (Fig. 4A). These inflammation-related gene
expression–driven phases were comparable with the phases of gene expression correlating
with EBOV GP RNA in serum (Fig. 2A).

Author Manuscript

K-means analysis of these transcripts further identified groups of potentially co-regulated
genes based on expression level and pattern (Fig. 4B) that generally correlated with viral
kinetics in either PBLs or serum. Transcripts in groups I (n = 183) and II (n = 34) were most
highly expressed from d7 to d13 (Fig. 4B). During this period, serum EBOV GP RNA levels
peaked (d8) followed by decline (Fig. 1A). After d13, expression levels of these transcripts
decreased but remained elevated until d25 before decreasing to near-baseline levels. During
this period, serum EBOV GP RNA levels continued to decline until they become
undetectable at d24. Groups I and II represent some of the most highly expressed transcripts
Sci Transl Med. Author manuscript; available in PMC 2018 April 12.
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at any time point and include classic antiviral response–related genes (IFIT1-3, ISG15,
IFI27, IFI35, and IFI44) and type I and II IFN signaling (OAS2, OAS3, Mx1, IRF7, and
IRAK3) that are likely important for attenuating viral replication. Upstream analysis
identified key antiviral response–related transcription regulators (STAT1, STAT2, STAT3,
and IRF1/IRF7) and multiple IFNs (IFNL1 and IFNα/β/γ) as upstream regulators (table
S10). That expression of these transcripts remained high despite a concomitant decrease in
serum EBOV RNA levels suggests a role in control of viral replication.

Author Manuscript
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Expression of transcripts in groups III (n = 61), IV (n = 375), and V (n = 229) were
generally consistent from d7 to d24, after which levels declined (table S10). Transcripts in
these groups were dominated by genes involved in T and B lymphocyte responses and
coincided with both clearance of EBOV RNA from peripheral blood and an increase in
Ebola-specific IgG titers (figs. S2 and S3). Sequences in group III were the most highly
expressed and remained elevated even at d270. Gene ontology analysis showed enrichment
for lymphocyte-related functions, including April-mediated signaling, B lymphocyte
activating factor signaling, interleukin-6 (IL-6) signaling, and granzyme A signaling.
Further, there were genes associated with lymphocyte homeostasis/ proliferation (CD70,
TNFRSF13B, TNFRSF17, IRF5, SOCS3, HAVCR2, and MAPK14) and protein folding/
trafficking (FKBP1A and HSPA5). Predicted upstream regulators of these sequences
included cytokines (CD40LG, IFN-γ, TNF, IFNα, IL-2, and IL-3) and the transcription
factor signal transducer and activator of transcription 1 (STAT1) that function in both innate
and adaptive immune responses (table S10). Transcripts in group IV were also enriched for
adaptive immune response functions, death receptor signaling, including the FAS pathway
(CASP8, CASP9, CFLAR, and FADD). Consistent with death receptor signaling, there was
enrichment of genes associated with epithelial cell death and lymphocyte development/
activation/proliferation, possibly reflective of cell-mediated immune responses targeting
infected cells. Predicted upstream regulators of this group were consistent with T and B
lymphocyte responses [including CD40LG, CD3, T cell receptor (TCR), IL-2, IL4, BCR,
and IFN-γ] (table S10). Transcripts in group V also represented processes required for
clearance of infected cells, including genes that regulate T lymphocyte development/
differentiation. In addition, neutrophil recruitment/activation (CCL3, CCL4, CD14, and
ITGAM), ROS, and macrophage/antigen-presenting cell–related genes were enriched,
possibly reflecting repair processes after cell-mediated tissue damage (table S10).
Collectively, immune response–related gene expression encompassing d7 to d24 was
dominated by T and B lymphocyte–mediated activity, coinciding with the steady decline and
subsequent clearance of EBOV RNA from serum, likely reflective of responses critical for
clearance of infected cells and development of protective immunity.

Author Manuscript

Groups VI (n = 95) and VII (n = 52) included transcripts with expression levels that
increased after viral clearance from serum (Fig. 4B). Sequences in group VI showed slightly
elevated levels until d24, at which time they increased further (table S10). Sequences in
group VII showed decreased levels relative to controls until d24 when they increased. The
expression level of transcripts in both groups remained elevated throughout the remaining
time points, coinciding with patient recovery. Some genes are involved in hematopoiesis/
immune cell function, including development of pro-T lymphocytes (BB3, CD3D, IL2RB,
CD27, Bax, and ZFPM1), recruitment of memory T lymphocytes (CCL5 and CCR10),
Sci Transl Med. Author manuscript; available in PMC 2018 April 12.
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differentiation of DC (CSFIR), and Nurr77 signaling (BCL2, MEF2D, and RXRA). These
processes may reflect renewal of homeostatic immune cell populations after viral clearance.

Author Manuscript

Total PBL numbers were elevated between d8 and d17 and again on d21 and d24, after
which they returned to normal range (4230 to 9070 cells/μl) (Fig. 4C). At no point during
the illness were they below normal range, although it is possible that leukopenia and
lymphopenia (commonly described during EVD) (13, 14) occurred in this patient before d7.
The monocyte population steadily increased beginning at d7 and was above normal range
(300 to 820 cells/μl) between d10 and d24, peaking at d15 and then declining (Fig. 4C). The
neutrophil population was elevated above normal range (1780 to 5380 cells/μl) from d8 to
d25 (Fig. 4C). Lymphocytes were within normal range (1320 to 3570 cells/μl) throughout all
but d14 to d15 when they were elevated, coinciding with clearance of NP vRNA from PBL.
The multiple phases of increased lymphocytes in PBL possibly reflected alternating
replenishment from lymphopoiesis and extravasation into tissues to target infected cells.
Notably, return of all immune cell subsets to normal range also coincided with clearance of
EBOV RNA from serum.
EVD is associated with moderate induction of key inflammatory chemokines and cytokines
that generally peak before critical illness phase of EVD

Author Manuscript

Dysregulated cytokine production has been linked to lethal EBOV infection (13–17). The
critical phase of illness (d10 to d19) was not associated with the highest levels of
inflammatory mediators at either the mRNA or protein level in this patient (figs. S6 to S9).
Increased mRNA levels of only limited inflammatory mediators were observed throughout
the time course, and levels generally peaked before d10. The expression profiles of
chemokines/receptors and cytokines/receptors that showed at least a twofold difference in
expression level at one time point are represented in Fig. 5 (A and B, respectively). Of
classical inflammatory mediators, only IL1-b mRNA was elevated relative to healthy
controls consistently from d7 to d12. IL-15 mRNA, which is secreted by monocytes in
response to viral infection and induces proliferation of natural killer (NK) cells (18) and
memory CD8 T cell survival (19), was increased until d12, and its subsequent decrease was
possibly related to clearance of EBOV NP mRNA in PBLs (Fig. 1A). The mRNAs encoding
several other cytokines, including IL-21, IL-26, IL-32, IL-11, IL-27, and IL-17F, were
transiently increased on isolated days. Expression levels of other cytokines that showed
differential regulation were decreased, suggesting either suppression or absence of cells that
express these mediators.

Author Manuscript

Chemokine mRNAs, particularly the CC class, were generally more highly and consistently
elevated than cytokines, although many also had levels lower than controls. The levels of
CCL3L3, CCL3, CXCL2, and CXCL1 mRNAs were generally higher at earlier time points,
although CCL3 continued to be elevated until later time points. CCL4 mRNA levels were
highest on d7 to d8 and d16 to d24, remaining elevated until well after viral clearance from
serum. CCL23 mRNA levels, highly chemotactic for resting T lymphocytes and monocytes
(20), were highest on d11 to d13, preceding an increase in peripheral lymphocyte and
monocyte populations (Fig. 4C). CCL25 mRNA levels, thought to play a role in recruiting
progenitor T lymphocytes to the thymus, were highest between d13 and d22, roughly
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coinciding with critical illness, but remained elevated until d28. Levels peaked at d15 that
corresponded to the highest PBL counts (Fig. 4C). Although not as highly induced as
CCL25, CXCL16 mRNA peak levels also corresponded generally to the critical phase of
illness (Fig. 5A). Transcript levels of many other chemokines (CCL15, CCL24, CCL21,
CCL27, CXCL5, and CXCL14) were lower than normal controls (Fig. 5B), particularly
during the presence of EBOV in serum.

Author Manuscript
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Selected cytokines and chemokines present in peripheral blood were also measured by
enzyme-linked immunosorbent assay (ELISA) (figs. S6 to S9) and generally supported
mRNA expression data in that many classical inflammatory mediators were not induced.
Those that were elevated typically peaked before onset of critical illness, when tissue injury
preceding organ failure was highest. Of cytokines measured, TNFα, IL-12p70, IL-2, IL-4,
and IL-5 (fig. S6) were not detectable above background at any time point. IL-1β was only
detected on d7, whereas other mediators were detectable on d7 to d8/d9 (IL-13, IL-17a, and
IFN-γ) (fig. S7). IL-8 was highest at d7, after which it decreased but remained detectable
until d22, just before clearance of virus from serum. Similarly, IL-10 decreased significantly
from d7 and became undetectable by d14. IL-6 levels were detectable from d7 followed by
an increase on d9, peaking on d11 and then decreasing rapidly to low levels and becoming
undetectable by d17. IL-7 was intermittently detectable (d7, d11, d12, d20, and d21) (fig.
S8). Granulocyte colony-stimulating factor (G-CSF), which stimulates production of
granulocytes (21), was highest on d7 and then decreased significantly by d8, just before an
increase in neutrophils between d9 and 10 (Fig. 4C and fig. S9). It remained detectable at
low levels until d22. Granulocyte-macrophage colony-stimulating factor (GM-CSF), which
stimulates production of granulocytes and monocytes (22), showed a similar expression
pattern, with the highest levels occurring on d7 to d8 and then decreasing until it was
undetectable by d12 (fig. S9). This was just before a gradual increase in monocytes that
occurred between d9 and d15 (Fig. 4C). The chemokines CCL2 (MCP-1) and CCL4
[macrophage inflammatory protein-1 β (MIP-1β)] were both elevated to varying degrees
(fig. S9). The levels of CCL2 were also highest on d7, decreasing on d8 but remaining
relatively constant until becoming undetectable on d14. Levels of CCL4 were also highest
on d7 but remained relatively high for all time points analyzed (up to d31), consistent with
increased mRNA expression until d103 (Fig. 5A). This observation, along with
inflammatory gene expression, suggests that some aspects of the inflammatory response
remained stimulated well after viral clearance from serum in this patient, possibly resulting
from maintenance of virus in immune-privileged sites such as the eye and testes (23–26).
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mRNAs encoding receptors for cytokines and chemokines generally showed higher and
more sustained expression than the ligands, particularly the cytokine and CXC class of
chemokine receptors (Fig. 5, A and B). Whereas some cytokine receptors (IL11RA, IL9R,
IL7, IL17RE, IL15RA, CXCR5, and CXCR7) showed decreased expression, many were
highly expressed over multiple days, including components of the IL-1 receptor (IL1R2,
IL1RN, and IL1R1), IL-18 receptor (IL18R1 and IL18RAP), and others (IL17RA, IL15RA,
IL10RB, IL4RB, IL6RA, IL21R, IL2RB, and IL2RA). Transcripts of many chemokine
receptors, including CCR1, CCR2, CCRL2, CCR5, CXCR1, CXCR3, and CXCR6, were
also highly expressed over multiple time points, whereas others showed decreased
expression (CCR3, CCR7, CXCR5, and CXCR7). Because chemokine/cytokine receptors
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are commonly expressed on immune cells, the general lack of high levels of CXC
chemokine/cytokine mRNAs may be more related to dysregulated immune cell function than
the absence of specific immune cell subsets.
Gene expression underlying clinical markers of coagulopathy suggest viral-mediated
death of macrophages, neutrophil activation, and increased phagocytosis of immune cells
during active viral replication
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Perturbations in coagulation have been observed during EVD (27–29). Abnormal platelet
levels, D-dimer (fibrin degradation product), and aPTT (activated partial thromboplastin
time) occurred between d7 and d15, consistent with coagulopathy previously described in
this patient (12). Specifically, D-dimer levels were elevated (>20 μg/μl) from at least d7,
returning to normal levels (5 μg/μl) around d16 (Fig. 6A). Platelet counts remained below
normal levels (lower limit of normal ∼150,000/μl) until d16, increased to almost 500, 000 at
d20, and then declined but remained within normal range through d33 (Fig. 6A).
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D-dimer and platelet levels throughout the illness were used as reference profiles to identify
transcripts whose expression level correlated with clinical parameters of coagulopathy to
better understand underlying pathological processes. Correlation analysis (≥0.6) identified
112 and 1516 transcripts that negatively and positively correlated with D-dimer levels,
respectively, between d7 and d33 and were also twofold differentially expressed in at least
four time points (fig. S10 and tables S11 and S12). Similarly, 1060 and 56 transcripts were
identified that negatively and positively, respectively, correlated with platelet levels between
d7 and d33 (fig. S11 and tables S13 and S14). Not surprisingly, there was significant overlap
in transcripts that showed positive correlation with D-dimer and negative correlation with
platelet levels (n = 1060) (table S15). Expression profiles of these transcripts, along with Ddimer and platelet levels, are shown in Fig. 6A. Most showed elevated expression levels that
decreased parallel to D-dimer levels decreasing and platelet levels increasing. These likely
represent cellular processes that were being attenuated after resolution of coagulopathy,
although they generally remained elevated to some degree beyond clinical resolution of
coagulopathy at d15.

Author Manuscript

Gene ontology analysis of these 1060 transcripts revealed enrichment for genes associated
with innate immune responses including macrophage/monocyte- and neutrophil-related
activities (Fig. 6, B and C). Specifically, expression of classic antiviral response genes
(including IFIT1, IFIT2, IFIT3, IFITM1, IFITM2, OAS1, OAS2, STAT1, and MX1) and
neutrophil recruitment/degranulation (CXCR1, CXCR2, and others) was increased
coincident with elevated D-dimer and depleted platelet levels (Fig. 6C). Genes involved in
macrophage recruitment (including IL1b, CCR1, and ITBG2), death (including
inflammasome-related NLRC4 and AIM2), and phagocytosis/engulfment of cells also
correlated with clinical parameters of coagulopathy (Fig. 6C). One possible explanation for
these gene expression changes is that coagulopathy results from viral replication and
associated cytopathic effect in macrophages and DCs. Subsequent engulfment of infected
cells by macrophages and neutrophils may then induce fibrin clot formation, possibly via
activated neutrophils mediating thromboinflammatory injury. The decrease in D-dimer levels
between d13 and d14 coincided with both clearance of EBOV NP mRNA from PBL by d12
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(Fig. 1A) and significant attenuation of antiviral response gene expression, with resolution
of coagulopathy occurring at d15.
Critical phase of illness characterized by decreasing serum EBOV RNA levels and
transitions in lymphocyte, cell death, and organ repair–related gene expression
The patient's clinical condition deteriorated from serious to critical on d10 to d19, after
which it was upgraded back to serious (12). This period reflected MOD associated with
EVD. These transition points correlated closely with serum creatinine levels, which began
rising at d10, peaked at d15, and returned to normal levels by about d20 (Fig. 7A).
Therefore, creatinine levels were used as a surrogate marker of transitions to and from
critical illness. Transcripts with expression kinetics correlating with serum creatinine levels
were identified to gain insight into possible pathological processes underling the critical
phase of illness.
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Expression profiles of 420 transcripts (table S16) showed a negative correlation with
creatinine levels and also a twofold difference in expression level compared to healthy
controls across at least three sample times (Fig. 7A). Most showed similar or slightly
decreased levels relative to healthy controls from d7 to d10, followed by a general decrease
until d14/d15, after which they returned to near baseline. A subset of these transcripts
showed increased expression relative to healthy controls on d7 to d10, followed by
decreased expression between d11 and d20, and subsequent return to increased levels
relative to healthy controls (Fig. 7A).

Author Manuscript
Author Manuscript

Gene ontology analysis of these transcripts showed enrichment for lymphocyte-related gene
expression including recruitment, development, differentiation, proliferation, and activation
of lymphocytes (Fig. 7B). Expression levels of certain lymphocyte activation markers
(FasLG, granzyme K, and ICOS), NK markers (KLRB1, KLRC3, and KLRD1), and T
lymphocyte markers (CD3D, CD83, CD8A, CD8B, and IL2RB) generally decreased from
d9 to d14/d15 and then began to increase until d18/d19 (fig. S12). In contrast, total
lymphocyte counts began increasing at d13 and peaked at d15 before decreasing again (Fig.
4C), suggesting that a subset of lymphocytes was leaving the periphery through either
apoptosis, as suggested by positive activation Z score for lymphocyte apoptosis (Fig. 7B), or
extravasation into tissues. Serum EBOV RNA level was continually dropping during this
phase (Fig. 1A), possibly as a result of cell-mediated immune responses targeting infected
tissue. EBOV is known to have a broad tissue tropism (3, 11), resulting in direct virally
mediated cytopathology and MOD. Organ injury leading to MOD was reached by d9/d10,
manifested by rising serum creatinine, down-trending but elevated hepatic enzymes, and
onset of respiratory failure (12). A transition to organ recovery was observed by d14/d15,
manifested by decreasing creatinine and normalization of hepatic enzymes and serum
creatinine phosphokinase levels. Cytotoxic T lymphocyte responses during this period of
critical illness likely contributed to viral clearance from tissues tipping the balance toward
tissue repair and recovery. This hypothesis is supported by the observation that
inflammation-related gene expression during this phase was dominated by adaptive immune
response markers and decreasing EBOV RNA levels (Fig. 4B).
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Positively correlated transcripts (n = 576) (table S17) generally showed slightly elevated
levels relative to healthy controls and began increasing at d10 parallel to serum creatinine
levels, peaking at d15 followed by gradual decrease, although they still generally remained
slightly elevated. Gene ontology analysis of these transcripts shows increased activity (based
on positive activation Z score) of numerous processes associated with tissue repair/recovery,
including cell survival, development/proliferation of endothelial cells and angiogenesis
(BMP6, ANG, GAS6, NCOA3, EDF1, PDCL3, PLOD3, SCARB1, and CLIC4), and
epithelial tissue development (Fig. 7B). Processes predicted to be decreased based on
expression level at d15 include organ death, apopto-sis, and necrosis (Fig. 7B).
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The immune-related genes were dominated by antiviral responses and adhesion/activation
(CD36, ITGB1, CCR2, and MIF) of antigen-presenting cells including macrophage/
monocytes (Fig. 7B). There was also enrichment of genes related with proliferation and
adhesion of immune cells (including IL27RA, CCR2, and CXCR3) and phagocytosis/
engulfment of cells (ClQA, CD36, Syk, Tusc2, and GAPVD1), possibly due to clearance of
apoptotic bodies resulting from lymphocyte targeting of infected cells. In support of this,
enriched pathways included the unfolded protein response (including ATF6, DNAJC3,
HSP90B1, and HSPA5) and NRF2-mediated oxidative stress response (such as DNAJC3,
DNAJC10, GSTP1, GSK3M, and TXNRD1) (fig. S13). Genes associated with oxidative
phosphorylation, the predominant mechanism used by lymphocytes to fuel their effector
functions (30), were also overrepresented and included ATP5G1, COX6B1, and numerous
genes encoding NADH–ubiquinone oxidoreductase subunits (NDUFA3, NDUFB7,
NDUFB11, NDUFS1, NDUFS7, NDUFS8, and NDUFV3) (fig. S13).
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Collectively, these data suggest that the critical phase of illness was associated with
declining serum EBOV RNA levels, possibly related to cell-mediated immune responses
targeting infected tissues, and increasing activation of organ repair processes. Further, peak
expression of these genes at d15 suggests that it represented a key transition point in patient
illness when underlying cellular processes shifted from cellular/ tissue damage to organ/
endothelium repair. d15 also corresponded to both peak serum creatinine levels and
peripheral lymphocyte counts and clearance of EBOV NP vRNA from PBL (Fig. 1A).
Subsequent decreasing levels of tissue repair–related gene expression likely reflected
attenuation of these responses, as viral/immune response–mediated tissue damage was
reduced after viral clearance along with reparative processes in tissues and organs.
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To understand the complexity of EVD in this patient, a plot integrating PBL gene
expression, antibody responses, and clinical symptoms (12) is shown in Fig. 8. Daily global
gene expression responses were spatially arranged into a two-dimensional coordinate system
using values from Eigen rows 1 and 2 derived from PCA of the gene expression data from
d7 through recovery and outpatient sampling. The timing of major clinical symptoms,
including diarrhea, fever, coagulopathy, and MOD, is overlaid. Diarrhea occurred during
peak serum and PBL EBOV RNA, as well as type IIFN responses. Virus-specific IgMs were
already present at low levels at d7 (fig. S14) and the appearance of GP-specific and wholevirus IgG around d14; neutralizing antibodies were not detected until after d21. During
recovery, “flare-ups” of PBL gene expression responses on d59 and d103 were observed;
however, these later samples were PCR-negative for GP RNA (fig. S15).
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Discussion
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Molecular correlates of disease severity, symptoms, and outcome during human EBOV
infection are just beginning to be elucidated. A large-scale study of T lymphocyte responses
in EVD cases during the 2013-2015 epidemic demonstrated differences in T lymphocyte
activation between survivors and fatalities (17). Specifically, increased expression of
inhibitory molecules CTLA-4 and PD-1 by CD8+ and CD4+ T cells correlated with greater
inflammatory responses and fatal infections. Kinetics and amplitude of viral replication have
also been shown to be an important factor in fatal versus nonfatal EVD (31–33). A report
demonstrated that patients with a qRT-PCR Ct of <24 had a 22% survival rate compared
with 87% survival in patients with Ct of ≥24 (34). Similarly, a study of seven patients with
EVD provided supportive care and different therapeutic interventions showed that more
severe disease was associated with increased viremia and higher expression of
proinflammatory- and coagulopathy-related biomarkers and decreased type I IFN responses
(29).
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Whereas expression of many proinflammatory cytokines and chemokines in this patient did
not peak until later in infection, expression of CCL3 (MIP-1α) peaked on or before d7,
suggesting the critical role of macrophage infection during early phases of EVD noted
previously (35, 36). The highest expression of several ISGs and the antiviral gene RSAD2
(viperin) occurred on the first day of PBL RNA sampling (d7) and then decreased, whereas
PBL EBOV NP mRNA increased through d9. EBOV NP mRNA and vRNA levels peaked in
PBLs at about d9 and then were no longer detected on d12 and d15, respectively, and
correlated with the marked decrease in type I IFN responses starting d14. This suggests that
expression of these genes was responsible, at least in part, for clearance of virus from PBLs,
along with virus-specific IgM already present at low levels at d7 and the appearance of GPspecific and whole-virus IgG around d14; neutralizing antibodies were not detected until
after d21. Activation of ROS, DNA damage, and macrophage cell death responses were also
highest during d7 to d13, but were not associated with concomitant loss of monocytes, but
rather an increase in monocytes peaking on d15. It is unclear whether clearance of EBOV
from PBLs was related to death of infected macro-phages, previously described in nonhuman primates (37), or if macrophages were able to halt viral replication without
undergoing death. d13 to d15 also marked the transition from an innate immune-dominated
to an adaptive immune-dominated response. Although liver dysfunction first appeared in this
patient before d7, and transition from tissue injury to repair occurred by d14/d15, features of
MOD in this patient persisted through d21 (12). The clinical grade of this patient was still
serious, but d21 marks a further transition in the equilibrium between damage and repair
responses that coincided with detection of neutralizing antibodies. Recovery in this patient
was marked by an overall decrease in infection-correlated gene expression responses that
persisted from discharge on d33 through d270, with observed flare-ups of PBL gene
expression responses on d59 and d103; however, these later samples were PCR-negative for
GP RNA. These data are compatible with recent studies showing persistent EBOV infection
in immune-privileged sites and prolonged recovery from EVD (23, 38–41). McElroy et al.
(29) also found evidence of robust T lymphocyte responses during EBOV infection, with
sustained activation of CD8 T lymphocytes long after clearance of virus from serum,
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suggesting continued antigen stimulation (11). However, these flare-ups could also indicate
exposure to other community-acquired viruses during outpatient sampling.
Although this patient had critical care support and recovered from EVD, severity of MOD
suggests a fatal outcome if care was provided in a more resource-limited setting. The peak
serum creatinine levels in this patient were consistent with those observed during fatal EVD
(27). Moreover, plasma levels of some cytokines/chemokines were generally more
consistent with levels reported for fatal cases (27). A patient evacuated from Sierra Leone to
Germany for treatment showed a similar disease course, where clinical condition
deteriorated after peak viral load and just before a significant drop in serum viral titers. This
also correlated with a rise in PBL and creatinine levels (42).
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Excessive cytokines, lymphocyte apoptosis leading to immuno-suppression, and absence of
antiviral IFN response have all been suggested to play a role in fatal EVD (13, 14, 16, 17).
Ruibal et al. (17) reported that plasma levels of selected cytokines (including TNF, IL8,
MIP-1α, and MIP-1β) were significantly higher in fatal EVD than in patients who survived.
A study of 42 nonsurvivors and 14 survivors from five separate EVD outbreaks found that
fatal outcomes were associated with hypersecretion of numerous proinflammatory cytokines
(14). Similarly, analysis of samples from the 2000 outbreak of Sudan virus in Uganda found
that levels of IL-6, IL-8, IL-10, and MIP-1b, but not IL-1B, IP10, or RANTES, were higher
in patients with fatal infections (15). Surprisingly, but similar to the current patient, levels of
TNF and IFN-γ were not generally increased compared to control patients (15). Although
differences in cytokine levels were considered statistically significant in some cases, there
was extensive variation in the levels among patients and sampling time with respect to
clinical course was generally not reported. Serum cytokine/chemokine levels measured in
the patient here were more consistent with levels reported for fatal cases but peaked several
days before onset of critical illness. Furthermore, TNF, a key proinflammatory cytokine, was
undetected in the serum, whereas IL-1β was only detected on d7. Because physiological
effects of cytokines are rapid and short-lived, with transcriptional responses typically
peaking within hours (43, 44), it is unclear what direct role, if any, they play in pathological
events underlying critical illness.
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Leukopenia has been reported in some cases of EVD (13, 16, 45, 46) and has been
correlated with severity of infection (13). Despite the severity of the infection in the current
patient, from d8, PBL populations were either within normal range or slightly elevated.
Lymphocytes were at lower range of normal at d7 and then increased, suggesting early
depletion and then recovery of this subset, with highest levels corresponding to critical phase
of illness. Gene ontology analysis of transcripts with expression kinetics corresponding with
serum creatinine levels, a surrogate marker for critical illness, predicted a decrease in
lymphocyte activity and increase in lymphocyte apoptosis based on decreased expression
levels of specific lymphocyte-related gene expression.
Lymphocyte apoptosis has been proposed as a cause of leukopenia during EVD (13, 14).
Elevated CD95 expression in T lymphocytes was reported to be responsible for massive
lymphocyte apoptosis, although no direct measurement of apoptosis was performed (14).
However, CD95 exerts both pro- and anti-apoptotic signaling and modulates TCR/CD3-
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driven signal initiation in a dose-dependent manner, with a high dose of CD95 agonist
(including CD95L) silencing T cells through blocking early TCR-driven induction, whereas
a lower dose of agonist actually augments lymphocyte activation/proliferation (47). Elevated
CD95 levels on lymphocytes may therefore not always be indicative of apoptosis. Sanchez et
al. (13) reported that fatal cases of EVD have reduced numbers of peripheral activated CD8+
T lymphocytes compared to survivors. However, these patients also had much higher levels
of serum EBOV RNA, and decreased circulating T lymphocyte populations could result
from these cells infiltrating infected tissues. Extensive lymphocyte apoptosis as a cause of
the decreased expression of T lymphocyte–specific genes cannotberuled outinthe current
patient becauseno direct measurementofapoptosis was conducted. However, changes in
peripheral lymphocyte numbers and decreasing serum viral levels suggest a subset of
lymphocytes leaving the PBL pool and targeting infected tissue. This scenario would also
result in decreased abundance of lymphocyte-specific gene expression in peripheral blood.
The question of apoptosis versus tissue infiltration is difficult to answer without analyses of
infected tissues.
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This study was limited to a detailed characterization of daily changes in PBL gene
expression responses in a single patient from early symptomatic disease to critical illness
and through recovery. While adding to our understanding of this patient's disease, it remains
to be shown how it applies in the larger context of human EVD, including both survivors and
fatalities. Nonetheless, it highlights the benefits of supportive medical care, as well as the
need to perform larger host response studies. Although we observed similarities between this
patient and studies in nonhuman primates (48–52), we also identified several important
differences such as a lack of a pronounced “cytokine storm” and absence of pronounced
lymphopenia during peak illness in this patient. Improving our ability to reduce severity and
high mortality rates of EVD will increasingly rely on studies that integrate critical care
medicine and detailed, longitudinal host response studies in both humans and nonhuman
primates.

Materials and Methods
Study design
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Daily blood samples were collected during inpatient care of an individual infected with
EBOV beginning before critical illness and continuing through recovery. Global expression
of RNA isolated from PBLs in these samples was measured by expression microarray. Each
RNA sample was labeled and hybridized in duplicate on individual arrays (n = 2). All
samples (except for d25 and d180) were analyzed by microarray twice (n = 4). Expression
data were correlated with other clinical information, including viral RNA concentration by
qRT-PCR, EBOV-specific antibodies by ELISA and PRNT80 assays, and D-dimer, platelet,
and serum creatinine measured using standard clinical microbiology laboratory methods.
The study was not blinded.
Patient information
Blood samples from the EBOV-infected patient (clinicaltrials.gov identifier NCT02363322)
and healthy volunteers (clinicaltrials.gov identifier NCT0138664) were obtained under
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clinical protocols approved by the National Institute of Allergy and Infectious Diseases
(NIAID) Institutional Review Board and were conducted in accordance with provisions of
the Declaration of Helsinki and good clinical practice guidelines. The clinical case of this
patient was previously described (12).
RNA isolation and expression microarray analysis
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Total RNA was isolated from whole blood using PAXgene Blood RNA Kit IVD (Qiagen)
and resuspended in TRIzol LS before removal from BSL-4 under supervision of the
Biosurety Program of the NIH and in accordance with Division of Select Agents and Toxins
at the Centers for Disease Control and Prevention. RNA quality was assessed using
Bioanalyzer (Agilent Technologies). Gene expression profiling was performed using Agilent
Human Whole Genome 44K microarrays. Fluorescent probes were prepared using Agilent
QuickAmp Labeling Kit. Each RNA sample was labeled and hybridized in duplicate on
individual arrays (n = 2) except for d25 and d180. Spot quantitation was performed using
Agilent's Feature Extractor software, and data were entered into the custom database
SLIMarray (http://slimarray.systemsbiology.net) and uploaded into Genedata Analyst 9.0
(Genedata). Complete MIAME-compliant (53) microarray data set has been deposited in the
National Center for Biotechnology Information (NCBI)'s Gene Expression Omnibus (GEO)
(54) and is accessible at GEO GSE93861. TIBCO Spotfire Analyst 6.0 was used for analysis
and heatmap creation.
WBC counts
WBC differential counts were performed at NIH Clinical Center by the Department of
Laboratory Medicine using standard methods.
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Quantitative EBOV and EBOV GP IgG ELISA
Serum samples and EBOV-specific IgG reference standard were serially diluted and
quantified using horseradish peroxidase-labeled anti-human IgG secondary antibody (KPL).
Detailed methods are in the Supplementary Materials.
EBOV IgM end titer ELISA
Serum samples were added to ELISA plates coated with irradiated whole EBOV antigen, as
described in (55). Detailed methods are in the Supplementary Materials.
Plaque reduction neutralization titration assay
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Serially diluted serum was mixed and incubated with 100 plaque-forming units of EBOV,
and percent neutralization was determined relative to wells treated with media alone, as
described in (55). Detailed methods are in the Supplementary Materials.
Quantitative cytokine analysis by Bio-Plex assay
Multiplex cytokine analysis was completed for serum samples using a magnetic bead–based
Bio-Plex Pro Human Cytokine 17-plex Assay kit (Bio-Rad) and FLEXMAP 3D instrument
(Luminex Corporation). Concentration of each sample analyte was determined using
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standard curves and reported as picograms per milliliter. Normal human serum (SigmaAldrich; catalog #H4522) was used as a negative control.
Quantitative reverse transcription polymerase chain reaction
Reverse transcription of equivalent amounts of total RNA was performed using SuperScript
III First-Strand Synthesis System (Life Technologies Inc.). Primers for Ebola NP vRNA
were as follows: forward, 5′-TCATGCGTACCAAGGAGATTAC-3′; reverse, 5′GCTTCACTCCATCACACTTCT-3′; probe, 5′-TCAAGTATTTGGAAGGGCACGGGT-3′.
Primers for Ebola NP mRNA were as follows: forward, 5′GCGTTAAGCCACAGTTATAGCC-3′; reverse, 5′GGGCAGGCTAGTAGGTAAGTTAT-3′; probe, 5′TGGTAACTCAATATCTTAGCCAGCGA-3′. qRT-PCR was performed in duplicate using
an ABI QuantStudio 6 Flex Real-Time PCR system.
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Statistics
Data normalization was performed in Genedata Analyst using central tendency followed by
relative normalization using pooled RNA isolated from blood of healthy volunteers (n = 29)
as a reference. Statistical analysis was performed using individual replicates. Pearson and
PCA were performed using Genedata Analyst 9.0. For Pearson correlation analysis, r ≥ 0.6
was used. For visualization, values from replicates were combined using arithmetic mean.
Ingenuity Pathway Analysis, Panther (56, 57), and Entrez Gene (www.ncbi.nlm.nih.gov/
gene) were used for gene ontology and pathway analysis using Bonferroni correction.

Supplementary Material
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Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Overall gene expression profile in peripheral blood shows distinct phases during EVD and
recovery

Author Manuscript

(A) Kinetics of EBOV NP mRNA and vRNA in PBLs as measured by strand-specific qRTPCR during course of illness. Serum EBOV GP RNA qRT-PCR data previously published in
(12) are shown for comparison with PBL replication. (B) Heatmap showing expression
levels of genes (n = 8660 sequences) that showed ≥2-fold change in expression level in at
least 30% of time points relative to a pool of 29 healthy adult volunteers. For all figures,
each heatmap column represents gene expression data from a microarray experiment
comparing patient peripheral blood at individual time points relative to pooled RNA isolated
from peripheral blood from healthy volunteers (n = 29). Genes shown in red were increased,
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genes shown in blue were decreased, and genes in black indicate no change in expression in
EVD patient relative to healthy volunteers. (C) Pairwise Pearson correlation coefficient
similarity matrix of expression values of these 8660 sequences. *Previously reported in (12).

Author Manuscript
Author Manuscript
Author Manuscript
Sci Transl Med. Author manuscript; available in PMC 2018 April 12.

Kash et al.

Page 24

Author Manuscript
Author Manuscript
Author Manuscript

Fig. 2. Gene expression correlating with kinetics of serum EBOV load
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(A) Pairwise Pearson correlation coefficient similarity matrix of expression values of
transcripts positively correlated (≥0.6) with EBOV GP RNA levels. (B) Heatmap showing
overall expression level of genes with positive (n = 2690 sequences) or negative (n = 1071
sequences) correlation with serum Ebola GP RNA (12). (C) Scatterplot showing relative
expression of genes at d13/d14. Red points indicate sequences with higher expression on
d13 (n = 2350), and blue points indicate sequences with higher expression on d14 (n = 655).
(D) Scatterplot showing relative expression of genes at d20 and d21. Red points indicate
sequences with higher expression on d20 (n = 550), and blue points indicate sequences with
higher expression on d21 (n = 431). (E) Scatterplot showing relative expression of genes at
d25/d28. Red points indicate sequences with higher expression on d25 (n = 132), and blue
points indicate sequences with higher expression on d28 (n = 1688).
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Fig. 3. Gene expression associated with Ebola viral replication in PBLs

(A) Quantification of EBOV NP mRNA (qPCR Ct) in PBLs and heatmap showing
expression of genes with positive correlation (≥0.6) with PBL EBOV NP mRNA. (B)
Heatmap showing expression levels of key ISGs. (C) Graph showing relative expression of
selected ISGs from (B) as determined by qRT-PCR. (D) Scatterplot showing relative
expression of cytokine signaling–related genes (n = 51) at d13/d14. (E) Scatterplot showing
relative expression of cell death–related genes (n = 29) at d13 and d14. Red points indicate
sequences with higher expression on d13, and blue points indicate sequences with higher
expression on d14.
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Fig. 4. Distinct phases of innate antiviral and adaptive immune response markers during EVD
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Analysis of inflammation-related gene expression (n = 1029 transcripts) with ≥2-fold change
in expression level in at least four individual time points. (A) Pairwise Pearson correlation
coefficient similarity matrix of expression values of these transcripts. (B) Heatmap showing
expression of innate antiviral and adaptive immune response markers. (C) Total white blood
cell (WBC) count and differential analysis of immune cell populations.
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Fig. 5. Strongest induction of inflammatory mediators and receptors generally occurred during
early EVD

Heatmaps depicting expression levels of mRNAs encoding chemokines/receptors (A) and
cytokines/receptors (B) during EVD and recovery. Gray indicates that the sequence was not
detected.
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Fig. 6. Gene expression correlating with clinical parameters of coagulopathy during EVD
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(A) Serum D-dimer (μg/ml, left axis) and platelet levels (K/μl, right axis) and heatmap
showing expression profiles of transcripts (n = 1016) with expression levels that are
correlated positively with serum D-dimer levels (≥.6) and negatively with platelet levels
(≤-0.6). (B) Gene ontology analysis of transcripts, with expression levels correlating with
serum D-dimer and platelet values (activation Z score is based on d10 expression values).
(C) Expression profiles of transcripts involved in macrophage recruitment, neutrophil
recruitment, antiviral response, macrophage cell death, degranulation, and phagocytosis.
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Fig. 7. Gene expression correlating with the critical phase of EVD

(A) Serum creatinine values (U/liter, left axis) and EBOV GP levels (qPCR Ct, right axis),
with heatmap showing expression profiles of transcripts with positive (≥0.6, n = 576) or
negative (≥−0.6, n = 420) correlation with serum creatinine levels. (B) Gene ontology
analysis of transcripts, with expression levels correlating with serum creatinine values
(activation Z score is based on d15 expression values).
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Fig. 8. Model of patient host responses and clinical disease
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PCA-derived model of patient PBL gene expression responses during illness course and
recovery. Day of illness is indicated by numbered circles colored by patient medical grade
and spatially arranged using Eigen row coordinates. (A) Host defense and immune response
markers correlated with peak viral load and clearance of replicating virus from PBL on d7 to
d13. (B) Activation of T lymphocytes and switch toward adaptive immune responses
associated with appearance of Ebola GP–specific IgG and declining serum EBOV RNA
levels on d14 to d15. (C) Continuation of adaptive immune responses and appearance of
virus-specific IgGs correlated with decreasing serum EBOV RNA and increased mitogenic
and metabolic responses on d16 to d20. (D) Adaptive immune and repair responses
associated with appearance of neutralizing antibodies and clearance of serum EBOV RNA
on d21 to d24. (E) Similarity of PBL gene expression before patient discharge on d25 to d33
and continuing in outpatient samples on d59 to d270. Timing of clinical symptoms (coagulopathy, diarrhea, fever, and MOD) is shown as reported in (12).
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